Allogene Therapeutics (ALLO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Allogene Therapeutics

NasdaqGS•Healthcare•Biotechnology

$1.74+0.00(<0.01%)Market open

Market Cap

$555.89M

P/S

119.8x

P/B

1.3x

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.

How this company scores

WeakMetricSide Score: 34/100

Grade capped at D — Interest coverage below 1× (-131.4x) — earnings cannot cover interest. Strongest: Profitability (11/25); weakest: Balance Sheet & Red Flags (7/25).

Profitability11/25

Growth8/25

Balance Sheet & Red Flags7/25

Cash & Earnings Quality8/25

Strengths

Profit converts from growthNet cash positionImproving margins

Grade capped at D

Interest coverage below 1× (-131.4x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 119.8x5y range 55.6x – 21083.9x

Currently below its 14-quarter median.

P/B · 1.3x5y range 0.7x – 3.6x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $555.89M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.64M
Q. Revenue: $4.64M
TTM EBITDA: $-168.65M
TTM Op. Income: $-180.32M
Q. Op. Income: $-46.92M
TTM Net Income: $-165.49M
Q. Net Income: $-42.68M
EPS: $-0.13
Shares Out.: $328.93M

$4.64M in TTM revenue grew from zero YoY, reaching $4.64M last quarter. TTM EBITDA of $-168.65M and TTM operating income of $-180.32M show growth is flowing through to the bottom line. However, net income is negative at $165.49M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is up 0% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -954.2%
Op. Margin: -1011.2%
Net Margin: -919.8%

Op. margin of -1011.2% is up 5681898988.8% YoY — cost efficiency is improving. Net margin at -919.8% Over the past year, operating margin is up 100% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 119.8x
P/B Ratio: 1.3x

P/S of 119.8x and P/B of 1.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $550.09M
Cash: $38.63M
Long-Term Debt: N/A
Book Value: $436.18M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-32.00M
TTM Free Cash Flow: $-102.60M
FCF Margin: -2211.2%
FCF / Net Income: 0.6

TTM FCF of $-102.60M on $-32.00M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Across the last 8 quarters, free cash flow has risen for 7 consecutive quarters — an improving trend.